Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27742621 | 0.98 | L3MBTL1 (0.48) | L3MBTL1SMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL648497 | 0.94 | NPC1 (0.50) | L3MBTL1SMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL2170934 | 0.86 | — | — | |
| SCHEMBL15641497 | 0.81 | SMN1; SMN2 (0.41) | L3MBTL1SMN1; SMN2ALDH1A1NPY5RHTR1A | |
| SCHEMBL5564524 | 0.80 | F13A1 (0.43) | L3MBTL1SMN1; SMN2NPY5RHTR1AHTR1D | |
| SCHEMBL12824314 | 0.79 | HSD17B10 (0.44) | L3MBTL1SMN1; SMN2ALDH1A1PKMHTR1A | |
| SCHEMBL5568640 | 0.79 | HRH3 (0.42) | L3MBTL1SMN1; SMN2ALDH1A1NPY5RHTR1A | |
| SCHEMBL28783104 | 0.79 | MEN1 (0.42) | L3MBTL1SMN1; SMN2NPC1RAB9ANPY5R | |
| SCHEMBL19161334 | 0.79 | ADORA2A (0.40) | L3MBTL1SMN1; SMN2ALDH1A1ADORA2APKM | |
| SCHEMBL21472632 | 0.79 | ADORA2A (0.49) | L3MBTL1SMN1; SMN2ADORA2ANPY5RHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114965723-B | Detection method of 2-acylaminothiazole compounds | 南京正大天晴制药有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116135854-A | Preparation method of 2-acylaminothiazole derivative maleate crystal form | 四川科伦药物研究院有限公司 | 2023-05-19 | — | — | CN | claimed |
| CN-115894475-A | Preparation method of acylamino thiazole compound | 四川科伦药物研究院有限公司 | 2023-04-04 | — | — | CN | claimed |
| EP-2314586-B1 | 2-Acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2016-09-14 | — | — | EP | claimed |
| US-20130287700-A1 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | KLINIKUM DARMSTADT GMBH (DE) | 2013-10-31 | — | — | US | claimed |
| EP-2619591-A2 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | Technische Universität Darmstadt (DE) | 2013-07-31 | — | — | EP | claimed |
| EP-2619590-A2 | COMPOUNDS FOR DIAGNOSING NEURODEGENERATIVE DISEASES AT THE RETINA | Technische Universität Darmstadt (DE) | 2013-07-31 | — | — | EP | claimed |
| EP-1466912-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-04-24 | — | — | EP | claimed |
| WO-2013041522-A1 | METHODS AND DEVICES FOR THE DETECTION OF TAU PROTEIN DEPOSITS IN EYES | CARL ZEISS AG (DE) | 2013-03-28 | — | — | WO | claimed |
| CN-102977088-A | 4-tertiary butyl-5-(1, 2, 4-triazole-1-base)-2-acylaminothiazole with bactericidal activity and method for preparing 4-tertiary butyl-5-(1, 2, 4-triazole-1-base)-2-acylaminothiazole with bactericidal activity | UNIV HUNAN | 2013-03-20 | — | — | CN | claimed |
| EP-1357116-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-10-29 | — | — | EP | claimed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | claimed |
| EP-0518731-B1 | 2-(Indol-2-yl-carbonylamino)-thiazole derivatives, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-08-26 | — | — | EP | claimed |
| EP-0432040-B2 | Heterocyclic derivatives of acylaminothiazole, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1997-12-17 | — | — | EP | claimed |
| US-5380736-A | Cholecystokinin and gastric antagonist | ELF SANOFI (FR) | 1995-01-10 | — | — | US | claimed |
| US-5314889-A | Hormone antagonists | ELF SANOFI (FR) | 1994-05-24 | — | — | US | claimed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | claimed |
| EP-0518731-A1 | Heterocyclic derivatives of substituted 2-acylamino 5-thiazole, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-12-16 | — | — | EP | claimed |
| US-5110921-A | Bactericides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | claimed |
| EP-0432040-A1 | Heterocyclic derivatives of acylaminothiazole, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1991-06-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287700-A1 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | SNCA, MAPT, TARDBP | L3MBTL1 3207/4885SMN1; SMN2 113/4885ALDH1A1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.